Skip to Content

Talaris Therapeutics, Inc.

Merger

  • Date:
  • 6/22/2023
  • Company Name:
  • Talaris Therapeutics, Inc.
  • Stock Symbol:
  • TALS
  • Company Name - Buyer:
  • Tourmaline Bio, Inc.
  • Status:
  • Investigating
  • Merger Announcement Date:
  • 6/22/2023

Case Finder

Locate any case using the tools below.

NEW YORK, June 22, 2023 – Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Talaris Therapeutics, Inc. (Nasdaq: TALS) (“Talaris”) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by Tourmaline Bio, Inc. (“Tourmaline”).

On June 22, 2023, Talaris announced that it had entered into an agreement to be acquired by Tourmaline in an all-stock deal. Pursuant to the merger agreement, Tourmaline stockholders are expected to own approximately 78.7% of the combined company, and Talaris stockholders are expected to own approximately 21.3% of the combined company, each on a fully diluted basis. The combined company will operate under the name Tourmaline Bio, Inc. and trade on the Nasdaq under the ticker symbol “TRML.” The deal is expected to close in the fourth quarter of 2023.

Bragar Eagel & Squire is concerned that Talaris's board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement. Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for Talaris stockholders.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Talaris Therapeutics. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: